NCT04905602

A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Administered SHR-1905 in Healthy Subjects and Subjects With Mild Asthma.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 86 (actual)
• Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study is a phase 1 single dose escalation study of SHR-1905 in healthy subjects and subjects with mild asthma. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of SHR-1905 in healthy subjects and subjects with mild asthma.

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	SHR-1905/placebo	Drug: SHR-1905 subcutaneous, single dose Drug: Placebo subcutaneous, single dose

Timeline

• Start date: 2021-06-15
• Primary completion: 2023-10-09
• Completion: 2023-10-09
• First posted: 2021-05-27
• Last updated: 2024-10-30

Locations

1 site across 1 country: China